Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway.

Katarzyna ŁosińskaAre Hugo PrippGunnstein BaklandBjørg-Tilde Svanes FevangLene Kristin BrekkeAda WierødMariusz KorkoszGlenn Haugeberg

Published in: Arthritis care & research (2024)

At one year, outcomes for PsA disease activity and drug persistence were comparable for patients treated with either ETN or SB4. In patients undergoing a mandatory nonmedical switch from ETN to SB4, drug effectiveness was maintained during a two-year period.

Keyphrases

disease activity
rheumatoid arthritis
rheumatoid arthritis patients
ankylosing spondylitis
systemic lupus erythematosus
juvenile idiopathic arthritis
patients undergoing
prostate cancer
randomized controlled trial
systematic review
adverse drug
drug induced
metabolic syndrome
radical prostatectomy
adipose tissue